I am a pediatric oncologist who treats children and young adults with leukemias and refractory solid tumors. In particular, I am interested in developing treatments that maximize the success of currently available therapies and devising new therapies that are precise, curative, and safe.
My research takes advantage of modern technologies to improve our understanding of the biologic causes of blood and solid tumors. Together with colleagues, I have made discoveries about new therapeutic targets in cancer cells, mechanisms by which cancer cells can evade new treatments, and improved strategies to overcome treatment resistance. I am a member of the Children’s Oncology Group, where I help to devise national clinical trials of improved treatments that leverage these advances. This work has been recognized by the Research Award from the Society of Pediatric Research (2009), Investigator Award from the Alliance for Clinical Trials in Oncology (2012), the Investigator Award from the American Society for Pediatric Hematology/Oncology (2013), and the Scholar Award from the American Society of Hematology (2014).
- Clinical Expertise: Leukemias and Refractory Tumors in Children and Young Adults
- Languages Spoken: English; Russian
- Education: MD, PhD, Mount Sinai School of Medicine
- Residencies: Boston Children's Hospital
- Fellowships: Boston Children's Hospital; Dana-Farber Cancer Institute
- Board Certifications: Pediatrics; Pediatric Hematology/Oncology
As home to one of the world’s top cancer research centers, Memorial Sloan Kettering is typically involved in more than 900 clinical trials at a given time. Currently, clinical trials focused on the conditions I treat are enrolling new patients. If you’re interested in joining a clinical trial, click to learn about the trial’s purpose, eligibility criteria, and how to get more information.Learn more